Study summary

The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.

Additional Study Details

Phase
4
Product
N/A
Product
Mirabegron
Placebo
Tamsulosin
Type
Interventional
Masking
Double (Participant, Investigator)
Enrollment number
568
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): Japanese
Protocol
Available Language(s): English
Statistical Analysis Plan (SAP)
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects with overactive bladder (OAB) Symptoms, while taking the Alpha Blocker for benign prostatic hypertrophy (BPH)? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site JP81053
    Osaka, Osaka, Japan
    Completed
    Site JP81027
    Osaka, Osaka, Japan
    Completed
    Site JP81021
    Tokyo, Tokyo, Japan
    Completed
    Site JP81014
    Tokyo, Tokyo, Japan
    Completed
    Site JP81005
    Gunma, Gunma, Japan
    Completed
    Site JP81056
    Kanagawa, Kanagawa, Japan
    Completed
    Site JP81008
    Saitama, Saitama, Japan
    Completed
    Site KR00003
    Seoul, Seoul, Republic of Korea
    Completed
    Site JP81007
    Saitama, Saitama, Japan
    Completed
    Site JP81046
    Aichi, Aichi, Japan
    Completed
    Site KR00001
    Seoul, Seoul, Republic of Korea
    Completed
    Site JP81020
    Tokyo, Tokyo, Japan
    Completed
    Site JP81003
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP81016
    Tokyo, Tokyo, Japan
    Completed
    Site JP81045
    Chiba, Chiba, Japan
    Completed
    Site JP81010
    Tokyo, Tokyo, Japan
    Completed
    Site JP81012
    Tokyo, Tokyo, Japan
    Completed
    Site JP81015
    Tokyo, Tokyo, Japan
    Completed
    Site JP81024
    Kanagawa, Kanagawa, Japan
    Completed
    Site JP81034
    Osaka, Osaka, Japan
    Completed
    Site JP81042
    Fukuoka, Fukuoka, Japan
    Completed
    Site KR00002
    Seoul, Seoul, Republic of Korea
    Completed
    Site JP81011
    Tokyo, Tokyo, Japan
    Completed
    Site JP81025
    Osaka, Osaka, Japan
    Completed
    Site JP81036
    Osaka, Osaka, Japan
    Completed
    Site JP81033
    Osaka, Osaka, Japan
    Completed
    Site JP81040
    Hyogo, Hyogo, Japan
    Completed
    Site KR00005
    Seoul, Seoul, Republic of Korea
    Completed
    Site JP81028
    Osaka, Osaka, Japan
    Completed
    Site JP81032
    Osaka, Osaka, Japan
    Completed
    Site JP81022
    Tokyo, Tokyo, Japan
    Completed
    Site JP81029
    Osaka, Osaka, Japan
    Completed
    Site JP81041
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP81050
    Shizuoka, Shizuoka, Japan
    Completed
    Site JP81001
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP81013
    Tokyo, Tokyo, Japan
    Completed
    Site JP81009
    Chiba, Chiba, Japan
    Completed
    Site JP81019
    Tokyo, Tokyo, Japan
    Completed
    Site JP81030
    Osaka, Osaka, Japan
    Completed
    Site JP81038
    Hyogo, Hyogo, Japan
    Completed
    Site JP81017
    Tokyo, Tokyo, Japan
    Completed
    Site JP81037
    Osaka, Osaka, Japan
    Completed
    Site JP81051
    Kochi, Kochi, Japan
    Completed
    Site JP81044
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP81052
    Kochi, Kochi, Japan
    Completed
    Site JP81031
    Osaka, Osaka, Japan
    Completed
    Site JP81043
    Fukuoka, Fukuoka, Japan
    Completed
    Site KR00004
    Seoul, Seoul, Republic of Korea
    Completed
    Site JP81039
    Hyogo, Hyogo, Japan
    Completed
    Site JP81002
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP81054
    Osaka, Osaka, Japan
    Completed
    Site JP81004
    Gunma, Gunma, Japan
    Completed
    Site JP81048
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP81035
    Osaka, Osaka, Japan
    Completed
    Site JP81047
    Kumamoto, Kumamoto, Japan
    Completed
    Site JP81018
    Tokyo, Tokyo, Japan
    Completed
    Site JP81026
    Osaka, Osaka, Japan
    Completed
    Site JP81006
    Saitama, Saitama, Japan

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?